Merrill Lynch Stick to Their Buy Rating for CVS Health Corp
Merrill Lynch analyst Michael Cherny maintained a Buy rating on CVS Health Corp (NYSE:CVS) on Tuesday, setting a price target of eighty three dolars, which is approximately 9.11 % above the present share price of $76.07. Cherny expects CVS Health Corp to submit earnings per share (EPS) of $0.93 for the earliest quarter of 2021. […]